Inhibitory Potential of Polyclonal Camel Antibodies against New Delhi Metallo-β-lactamase-1 (NDM-1).


Journal

Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009

Informations de publication

Date de publication:
28 Sep 2020
Historique:
received: 30 07 2020
revised: 08 09 2020
accepted: 09 09 2020
entrez: 1 10 2020
pubmed: 2 10 2020
medline: 20 3 2021
Statut: epublish

Résumé

New Delhi Metallo-β-lactamase-1 (NDM-1) is the most prevalent type of metallo-β-lactamase, able to hydrolyze almost all antibiotics of the β-lactam group, leading to multidrug-resistant bacteria. To date, there are no clinically relevant inhibitors to fight NDM-1. The use of dromedary polyclonal antibody inhibitors against NDM-1 represents a promising new class of molecules with inhibitory activity. In the current study, immunoreactivities of dromedary Immunoglobulin G (IgG) isotypes containing heavy-chain and conventional antibodies were tested after successful immunization of dromedary using increasing amounts of the recombinant NDM-1 enzyme. Inhibition kinetic assays, performed using a spectrophotometric method with nitrocefin as a reporter substrate, demonstrated that IgG1, IgG2, and IgG3 were able to inhibit not only the hydrolytic activity of NDM-1 but also Verona integron-encoded metallo-β-lactamase (VIM-1) (subclass B1) and L1 metallo-β-lactamase (L1) (subclass B3) with inhibitory concentration (IC

Identifiants

pubmed: 32998307
pii: molecules25194453
doi: 10.3390/molecules25194453
pmc: PMC7584030
pii:
doi:

Substances chimiques

Antibodies 0
Immune Sera 0
Immunoglobulin G 0
beta-lactamase L1 EC 3.5.2.-
beta-Lactamases EC 3.5.2.6
beta-lactamase NDM-1 EC 3.5.2.6

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

Lancet Infect Dis. 2010 Sep;10(9):597-602
pubmed: 20705517
Appl Microbiol Biotechnol. 2007 Nov;77(1):13-22
pubmed: 17704915
BMC Microbiol. 2017 Apr 27;17(1):101
pubmed: 28449650
Biochem J. 2009 Nov 11;424(2):263-72
pubmed: 19732033
Nucleic Acids Res. 2000 Jan 1;28(1):235-42
pubmed: 10592235
Clin Microbiol Rev. 2010 Jan;23(1):160-201
pubmed: 20065329
Crit Rev Microbiol. 2017 Feb;43(1):43-61
pubmed: 27387224
Int J Mol Sci. 2020 May 18;21(10):
pubmed: 32443639
Antimicrob Agents Chemother. 2001 Oct;45(10):2807-12
pubmed: 11557473
Toxicon. 2003 Dec;42(7):785-91
pubmed: 14757210
Antimicrob Agents Chemother. 2018 Sep 24;62(10):
pubmed: 30061284
Expert Rev Anti Infect Ther. 2014 Jan;12(1):91-115
pubmed: 24308710
Biochem Pharmacol. 1987 Jul 15;36(14):2393-403
pubmed: 3038122
Nature. 1993 Jun 3;363(6428):446-8
pubmed: 8502296
J Glob Antimicrob Resist. 2019 Sep;18:80-87
pubmed: 30763762
Drug Discov Today Technol. 2010 Summer;7(2):e95-e146
pubmed: 24103724
Proteins. 1998 Sep 1;32(4):515-22
pubmed: 9726420
J Biotechnol. 2001 Jun;74(4):277-302
pubmed: 11526908
J Antimicrob Chemother. 2019 Aug 1;74(8):2197-2202
pubmed: 31065697
Antimicrob Agents Chemother. 2000 Nov;44(11):3003-7
pubmed: 11036013
ACS Med Chem Lett. 2017 Nov 26;9(1):45-50
pubmed: 29348810
Microb Drug Resist. 2020 Jun 2;:
pubmed: 32486911
Curr Protein Pept Sci. 2017;19(2):130-144
pubmed: 28745223
Lancet Infect Dis. 2011 May;11(5):381-93
pubmed: 21530894
Antimicrob Agents Chemother. 2019 Mar 27;63(4):
pubmed: 30917978
Drug Discov Today. 2016 Jul;21(7):1076-113
pubmed: 27080147
Vet Immunol Immunopathol. 2009 Mar 15;128(1-3):178-83
pubmed: 19026455
J Biol Chem. 2002 Jul 5;277(27):24142-7
pubmed: 11967267
EMBO J. 1998 Jul 1;17(13):3512-20
pubmed: 9649422
Biochem J. 2013 Mar 15;450(3):477-86
pubmed: 23289540
PLoS One. 2018 Jan 2;13(1):e0189686
pubmed: 29293526
Trends Microbiol. 2011 Dec;19(12):588-95
pubmed: 22078325
Adv Exp Med Biol. 2019;1145:9-13
pubmed: 31364068
Philos Trans R Soc Lond B Biol Sci. 1980 May 16;289(1036):321-31
pubmed: 6109327
Protein Sci. 2009 Mar;18(3):619-28
pubmed: 19241371
Antimicrob Agents Chemother. 2004 Jul;48(7):2347-9
pubmed: 15215079
FASEB J. 2010 Sep;24(9):3479-89
pubmed: 20410443
CMAJ. 2011 Aug 9;183(11):1240-1
pubmed: 21788418
Cold Spring Harb Perspect Med. 2016 Aug 01;6(8):
pubmed: 27329032

Auteurs

Rahma Ben Abderrazek (R)

Laboratoire des Venins et Biomolécules Thérapeutiques, Institut Pasteur Tunis, Université Tunis El Manar, 13 Place Pasteur, BP-74, 1002 Tunis, Tunisie.

Sarra Chammam (S)

Laboratoire des Venins et Biomolécules Thérapeutiques, Institut Pasteur Tunis, Université Tunis El Manar, 13 Place Pasteur, BP-74, 1002 Tunis, Tunisie.

Ayoub Ksouri (A)

Laboratoire des Venins et Biomolécules Thérapeutiques, Institut Pasteur Tunis, Université Tunis El Manar, 13 Place Pasteur, BP-74, 1002 Tunis, Tunisie.

Mariagrazia Perilli (M)

Dipartimento di Scienze Cliniche Applicate e Biotecnologiche, Università degli Studi dell'Aquila, Via Vetoio, I-67100 L'Aquila, Italy.

Sayda Dhaouadi (S)

Laboratoire des Venins et Biomolécules Thérapeutiques, Institut Pasteur Tunis, Université Tunis El Manar, 13 Place Pasteur, BP-74, 1002 Tunis, Tunisie.

Ines Mdini (I)

Laboratoire des Venins et Biomolécules Thérapeutiques, Institut Pasteur Tunis, Université Tunis El Manar, 13 Place Pasteur, BP-74, 1002 Tunis, Tunisie.

Zakaria Benlasfar (Z)

Laboratoire des Venins et Biomolécules Thérapeutiques, Institut Pasteur Tunis, Université Tunis El Manar, 13 Place Pasteur, BP-74, 1002 Tunis, Tunisie.

Gianfranco Amicosante (G)

Dipartimento di Scienze Cliniche Applicate e Biotecnologiche, Università degli Studi dell'Aquila, Via Vetoio, I-67100 L'Aquila, Italy.

Balkiss Bouhaouala-Zahar (B)

Laboratoire des Venins et Biomolécules Thérapeutiques, Institut Pasteur Tunis, Université Tunis El Manar, 13 Place Pasteur, BP-74, 1002 Tunis, Tunisie.
Faculté de Médecine de Tunis, Université Tunis El Manar, 15 Rue Djabel Lakhdar, 1007 Tunis, Tunisie.

Alessandra Piccirilli (A)

Dipartimento di Scienze Cliniche Applicate e Biotecnologiche, Università degli Studi dell'Aquila, Via Vetoio, I-67100 L'Aquila, Italy.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH